Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates.

Tetsuya KanekoKoichi OkamuraYukio YonemotoChisa OkuraTakahito SutoMasahiro TachibanaHideo SakaneMakoto InoueHirotaka Chikuda

Published in: Journal of experimental orthopaedics (2019)

The effects of denosumab on BMD and BTMs of the switch group after long-term BP treatment are comparable to those of the naïve group in RA patients. Thus, switching BPs to denosumab is one of the useful options to treat osteoporosis with RA.

Keyphrases

bone mineral density
postmenopausal women
rheumatoid arthritis patients
body composition
disease activity
rheumatoid arthritis
end stage renal disease
ejection fraction
newly diagnosed
ankylosing spondylitis
prognostic factors
patient reported outcomes
patient reported
replacement therapy